Acromegalics have been reported to be at an increased risk of colorectal neoplasm. However, the magnitude of the risk is still controversial and the mechanism has not been fully investigated. In this study, we attempted to determine the magnitude of the association between acromegaly and colorectal lesions after taking into account age, gender, smoking status, and treatment status. In addition, we assessed the relationship between colorectal lesions and serum growth hormone (GH) levels in acromegalics.
INTRODUCTION
Acromegaly is a disease caused by excess secretion of growth hormone (GH), which is characterized by enlarged acral parts, coarse facial features, and visceromegaly. Acromegalic patients have a reduced life expectancy primarily due to cardiovascular, respiratory, or cerebrovascular disease (1) (2) (3) (4) (5) . Acromegalics may also be at an increased risk for malignancies in several systems including the digestive tract, brain, kidney, breast, prostate, and possibly the hematological system (6) (7) (8) (9) (10) . Colon cancer incidence rates (6, 7, 10) and mortality rates (9) have been reported to be higher in acromegalics than expected. A substantial number of reports also suggest that acromegaly is associated with an increased risk of colorectal neoplasm (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) . However, reported relative risks of colorectal cancer vary significantly depending on the study population and the study design. Colon cancer relative risk estimates in acromegalic patients have therefore ranged from 1.7 (9) to 10.4 (27) . In a study taking account of age, the estimated relative risk for subjects over 50 yr ranged from 6.8 to 18.3 (27) . However, most studies have not adjusted for known risk factors of colorectal cancer, and thus the true risk of colorectal cancer is still unknown. Furthermore, previous studies have included both treated and untreated acromegalic patients; thus, treatment status may confound the association between acromegaly and colorectal neoplasm. In order to determine the true risk of colorectal cancer in acromegalic patients, known risk factors of colorectal cancer and treatment status need to be taken into account.
Hyperplastic polyps are generally considered to be benign lesions, with no malignant potential. Histologically, hyperplastic polyps are characterized by elongated and branched crypts showing epithelial hyperplasia in the proliferative zone and by the slow migration of colonic maturing cells upward along the crypt (28) . This histological condition is attributed to non-neoplastic cellular proliferation of the colonic epithelium. Hyperproliferation is a cytokinetic abnormality frequently seen in the mucosa of patients with colorectal neoplasm (29) and may relate to the development of colorectal neoplasms. In acromegalic patients, colonic mucosal proliferation is accelerated compared to normal controls (25, 30) . There is also some evidence showing increased prevalence of hyperplastic polyps as well as adenomas and carcinomas in the colorectum of acromegalics (18, 19) . Until now, only one study has shown an association between the frequency of colorectal neoplasm and serum GH level (26) . Considering the higher risk of colorectal neoplasm in acromegaly, it would be interesting from a pathophysiological point of view to assess the relationship between serum levels of GH and prevalence of colorectal lesions.
We conducted a case-control study by using untreated acromegalic patients to determine the association between acromegaly and colorectal neoplasm, after adjusting for age, gender, and smoking status. We also assessed the relationship between serum levels of GH and the presence of hyperplastic polyp, adenoma, and carcinoma.
MATERIALS AND METHODS

Study Population
Between 1990 and 2000, 32 acromegalic patients were seen at the Second Department of Internal Medicine, Kanazawa University Hospital. Of the 32 patients, 19 were newly diagnosed with acromegaly during the period. In order to avoid the potential confounding effects of treatment status, we used these 19 untreated acromegalic patients in this study to determine the association between colorectal lesions and acromegaly and the association between serum GH levels and colorectal lesions. The diagnosis of acromegaly was confirmed by the endocrinologists based on clinical, hormonal, and radiological features.
Seventy-six control subjects were randomly selected from patients who underwent total colonoscopy at our institution between 1990 and 2000. A total of 1,065 patients underwent total colonoscopy during the period for reasons of various abdominal symptoms or signs. Out of 1,065, we excluded 174 subjects (1) who had inflammatory bowel disease (n = 54), (2) who had a recent history of polypectomy (≤3 yr; n = 11), (3) whose records were unclear in terms of observed colonic segments (n = 15), and (4) who had any lesions not histologically examined (n = 94). Of the remaining 891 subjects, we randomly selected four age-, gender-, and smoking statusmatched controls for each of the 19 acromegalic patients (4 × 19 = 76). Controls were matched to cases within 10-yr age intervals: 10-19, 20-29, 30-39, 40-49, 50-59, 60-69, and 70-79 yr old. Current smokers were defined as those who smoked more than 10 cigarettes per day, while nonsmokers were defined as those who had never smoked before.
Colonoscopy
All acromegalic patients underwent colonoscopy when admitted for the first diagnosis of acromegaly. None of the patients had a history of polypectomy or colorectal surgery. In the control group, patients underwent colonoscopy for various reasons, including fecal occult blood, abdominal pain, abdominal tenderness, diarrhea, and anemia.
Total colonoscopy was performed after careful bowel preparation with 2 L of a polyethylene glycol-electrocyte oral lavage solution (Niflec, Ajinomoto-Farma, Inc., Japan). Colonoscopy was performed by several experienced gastroenterologists. In one acromegalic patient who had an obstructive colon cancer at the ascending colon, the proximal site incapable of being observed by colonoscopy was evaluated by surgical specimen. In the other acromegalic patients and all of the controls, the colon was examined from rectum through cecum by colonoscopy. All lesions visualized in colonoscopy were separately recorded and, where possible, the lesions were biopsied and histologically examined.
Serum Growth Hormone
GH was measured in the serum samples obtained in the morning after 8 h fasting when patients were hospitalized for their first evaluation of acromegaly. We used a two-site immunoenzymometric assay (ST-AIA PACK HGH, TOSOH Corporation, Japan). In this assay, anti-GH monoclonal antibody binds to magnetic beads. Serum GH was exposed to the bead-bound antibody in solution. After adding enzymelabeled anti-GH monoclonal antibody to the solution, magnetic beads were washed to remove any unbound enzyme-labeled monoclonal antibody and then incubated with a fluorogenic substrate, 4-methyl-umbelliferyl phosphate. Enzyme activity was measured fluorophotometrically and the concentration of serum GH was determined with use of calibration curves. The normal range of serum GH level is less than 5 ng/mL. Accuracy measured as recovery ranged from 94.6% to 95.2%, 91.6% to 93.5%, and 102.3% to 105.3% in three serum pools of different concentrations. Intra-and interassay coefficients of variation were 0.9-1.3% and 2.7-4.0%, respectively.
Statistical Analyses
Data are reported as mean ± standard deviation or number (proportion) of patients with a condition. To assess the risk of colorectal lesions in acromegalic patients, we performed conditional logistic regression and calculated odds ratios for each colorectal lesion with 95% confidence intervals (CI).
To assess the relationship between serum levels of GH and the presence of hyperplastic polyp, adenoma, and carcinoma, we compared serum levels of GH between the groups with and without each type of lesion using t-tests on logarithmically transformed data. In order to adjust for other colonic lesions and age, we performed a multiple linear regression analysis by using the logarithm of serum GH as an outcome variable and age, the presence of hyperplastic polyp, adenoma, and carcinoma as explanatory variables.
Analyses were conducted using Stat View statistical software version 4.1 (Abacus Concepts, Inc.) and JMP statistical software version 4.0.4 (SAS Institute, Inc.). Differences were considered statistically significant when p-values were less than 0.05.
RESULTS
The clinical characteristics and colorectal lesions of the 19 acromegalic patients are summarized in Table 1 . Eleven were 
* Smokers (noted as '+') are subjects who are smoking more than 10 cigarettes per day and nonsmoker (noted as '−') are subjects who had never smoked before. * * '±' indicates the presence of each lesion, yes or no. P, D, and B indicate the location of the colorectal lesions. 'P' indicates proximal colon (from cecum to transverse colon), 'D' indicates distal colon (from descending colon to rectum), and 'B' indicates both proximal colon and distal colon. 'No. of disc.' is the number of matched pairs for this case that did not have the same corresponding lesion status as the case. Two cases (nos. 10 and 18) had multiple hyperplastic polyps and these hyperplastic polyps were predominantly located at proximal colon. None of acromegalic patients had family history of colorectal cancer. One case (no. 11) had past history of malignancy (gastric cancer). male and eight were female. Mean age at diagnosis was 46.7 ± 16.3 yr (range: 15-73). Among the cases, none had a family history of colorectal cancer. One had a past history of advanced gastric cancer, but none had a past history of colorectal adenoma or cancer.
We had 100% matching success for gender and smoking. With respect to age, the mean ages with standard deviations were 46.8 ± 16.3 and 47.3 ± 16.5 yr old for cases and controls, respectively.
Thirteen of 19 cases (68.4%) had at least one colorectal lesion. Seven (36.8%) had hyperplastic polyps, 8 (42.1%) had adenomas (all had tubular adenomas and 1 had a tubulovillous adenoma simultaneously), and 3 (15.8%) had carcinomas as shown in Figure 1 . In the matched controls, 5 (6.6%) had hyperplastic polyps, 13 (17.1%) had adenomas, and 2 (2.6%) had carcinomas (Fig. 1) . The prevalence of hyperplastic polyps, adenoma, and carcinoma were significantly higher in acromegalic patients. The odds ratios of colorectal lesions in acromegalic patients to the age-, gender-, and smoking status-matched controls were 8. Serum levels of GH in acromegalic patients with and without each type of colorectal lesion are shown in Figure 2 . Univariately, patients with hyperplastic polyps, but not with adenoma or carcinoma, had significantly higher levels of serum GH (52.1 ± 28.5 ng/mL vs 29.7 ± 18.2 ng/mL, p < 0.05, ttest with logarithmic transformation) (Figs. 2A-C) compared to patients without these lesions. However, after adjusting for the other colorectal lesions and age, presence of hyperplastic polyp and carcinoma was significantly associated with higher levels of serum GH ( p < 0.01 and p < 0.006, respectively, multiple linear regression) (Figs. 2D-F , the model is shown in the figure legend). Based on the model, the predicted Partial residual of Hyperplastic polyp Partial residual of log GH Figure 2 . Association between serum GH levels and hyperplastic polyp, adenoma, and carcinoma. The box plots compare serum GH levels (ng/mL), between acromegalic patients with and without (A) hyperplastic polyp, (B) adenoma, and (C) carcinoma. The horizontal axis plots patients groups either with or without each type of colorectal lesion, while the vertical axis gives serum GH values. Horizontal bars in the middle of the boxes indicate median values, and the vertical length of the boxes indicates interquarter ranges. The whiskers indicate outermost data points within 1.5 times the interquarter range as measured from the ends of each box. The mean ± standard error of serum GH levels in the groups with and without hyperplastic polyp, adenoma, and carcinoma were 52.1 ± 28.5 versus 29.7 ± 18.2, 34.4 ± 21.5 versus 40.5 ± 27.0, and 48.6 ± 16.3 versus 36.0 ± 25.5 (t-test with logarithmic transformation: p < 0.05, p = 0.43, and p = 0.23, respectively). The partial regression plots show relationship between the logarithm of serum GH levels and the presence of (D) hyperplastic polyp, (E) adenoma, and (F) carcinoma after adjusting for the presence of the other colonic lesions. In each plot, solid line represents a regression line, and dotted curves represents 95% confidence curve. The vertical axis plots partial residuals of the logarithm of serum GH, while the horizontal axis plots partial residuals of hyperplastic polyp, adenoma, or carcinoma. The partial residuals are derived from a multiple linear regression model of the logarithm of serum GH as an outcome variable and binary variables of the presence of hyperplastic polyp, adenoma, and carcinoma as explanatory (The model: log GH = 3.58 − 0.01 * age + 0.82 * HP − 0.43 * AD + 1.38 * CA). The presence of hyperplastic polyp and carcinoma was significantly associated with higher levels of the logarithm of serum GH after adjusting for the presence of the other colorectal lesions and age ( p < 0.01 for hyperplastic polyp and p < 0.006 for carcinoma).
median levels of serum GH of the patients with hyperplastic polyps or carcinoma were 2.3 or 4.0 times greater compared to patients without these lesions.
DISCUSSION
In this study, we assessed the risk of colorectal lesions in untreated acromegalic patients by using age-, gender-, and smoking status-matched hospital controls. We found that untreated acromegalic patients had a significantly higher prevalence of hyperplastic polyp, adenoma, and carcinoma in the colorectum compared to controls. Also we found that the presence of hyperplastic polyp and the presence of carcinoma were significantly associated with higher levels of GH after adjusting for other types of colorectal lesions and age.
During the last two decades, the risk of colorectal neoplasm in acromegaly has been actively investigated. Most studies have suggested that acromegalic patients are at an increased risk of colorectal adenomas and carcinomas. However, the magnitude of the risk in these studies varies depending on the study designs and populations. Since known risk factors for colorectal cancers and treatment status might confound the association between acromegaly and colorectal lesions, we used newly diagnosed acromegalic patients (i.e., untreated) as cases, and nonacromegalic hospital patients matched for age, gender, and smoking status as controls.
In this study, the estimated odds ratio of colorectal cancer in acromegaly was 9.8 after taking into account age, gender, and smoking status. The odds ratio of 9.8 lies in the middle of recently reported estimates. There are two rather polarized ranges of estimates in the previous literature; one ranging from 1-to 3-fold (7, 9, 10, 31, 32) and the other ranging from 13-to 14-fold (33) . The former estimates are based on population-based studies and a study using autopsy controls. The population-based studies included any acromegalic patients, inactive as well as active, and long-standing as well as initial cases, all of which may have confounded the relation between acromegaly and colon cancer, and artificially lowered the risk estimates. On the other hand, the study using autopsy to detect colorectal lesions for cases and controls may have also resulted in a biased estimate. Since autopsy examination is more sensitive than colonoscopy, this bias may also artificially lower risk estimates. The latter estimates are based on studies using hospital controls similar to this study. In the previous studies, however, potential confounders such as treatment status and smoking status were not taken into account. In this study, we matched by age, gender, and smoking status and used only newly diagnosed, untreated acromegalic patients. Also, both cases and controls were examined over their entire colorectum by several experienced gastroenterologists who worked in the hospital. Although there may be some unmatched age effects (10-yr age intervals were used), our risk estimate of 9.8 was adjusted for these factors. Regarding family history of colorectal cancer, which is regarded as a risk factor for colorectal cancer, none of the acromegalic patients or the 76 controls had a family history of colorectal cancer. Thus, this would not (in this study at least) confound our estimates. Since we used hospital controls that had clinical reasons to undergo colonoscopies, our controls may (in some way) be associated with a higher risk of colorectal cancer compared to the general population. This may actually artificially lower our risk estimate to some extent. Our population was rather small, resulting in low statistical precision. Therefore, our estimate needs to be confirmed in a larger prospective study.
In this study, we also showed that the presence of hyperplastic polyp and carcinoma were significantly associated with higher serum levels of GH after adjusting for the other type of colorectal lesions. In acromegalic patients, fasting GH levels inversely correlates with age (36) . In this study, the association between the presence of hyperplastic polyps and carcinoma and elevated serum GH was seen even after taking account of age. The majority of previous studies showed no association between serum GH level and the frequency of colorectal neoplasm in the acromegalic patients (11, 18, 20, 21, 31, 34) . Only a few studies have shown an association between incidence or mortality of colorectal neoplasm and serum GH levels (9, 26, 35) . A large cohort study showed that higher post-treatment serum GH levels were associated with a higher mortality rate of colon cancer (9) . Also, another recent study showed that acromegalic cases with elevated GH or insulin-like growth factor-I (IGF-I) levels were associated with higher mortality of malignancy compared to those with normal GH or IGF-I levels (35) . Another study showed a positive correlation between the incidence of colonic adenomas and serum GH levels at follow-up colonoscopy (26) .
The mechanism of the association between GH/IGF-I and colorectal neoplasm remains uncertain. However, mucosal hyperproliferation caused by GH/IGF-I may be related to the development of colorectal neoplasm. There is some evidence showing an association between serum GH/IGF-I and mucosal hyperproliferation. Cats et al. showed that the labeling index in the crypts of colonic mucosa was elevated in acromegalic patients compared to normal controls and was positively correlated with serum GH/IGF-1 (30). Jenkins et al. also showed increased mitotic counts and decreased apoptosis in acromegalic patients compared to nonacromegalic controls (25) . On the other hand, in the nonacromegalic population, it was shown that a hyperproliferative state was predominantly observed in colonic mucosa with colorectal adenomas, carcinomas, or hyperplastic polyps, compared to the mucosa without these lesions (29) . Thus, it is conceivable that a hyperproliferative state caused by elevated GH/IGF-1 may, at least to some extent, relate to a higher prevalence of colorectal neoplasm in acromegaly. Since we used only untreated cases in this study, treatment status did not confound our study results. This could explain why we observed a relationship between acromegaly and colorectal neoplasias even in our smaller population.
Another possible mechanism is hyperinsulinemia commonly seen in acromegaly. Since 16-46% of patients with acromegaly also have impaired glucose tolerance (IGT) (37) , patients with acromegaly likely have elevated levels of serum insulin. In our patients, 36.8% of cases also had IGT and 45.5% of cases had serum insulin levels greater than 10 µg/mL. Although we did not see any significant association between serum insulin levels and any colonic lesions (data not shown, n = 11), serum insulin levels may have confounded the association seen between serum GH and colonic lesions. At this point, the factor(s) truly related to colonic tumorigenesis (IGF-1, GH, other abnormalities caused by elevated GH levels, or the combination of them) remains uncertain. Further studies are needed to address the causal relationship between hormonal abnormalities seen in acromegaly and colonic neoplasm.
In this study, the prevalence of hyperplastic polyp was also higher in acromegalic patients and associated with higher serum GH levels. Data regarding hyperplastic polyp in acromegaly are limited. However, there are several studies showing a higher prevalence (or incidence) of hyperplastic polyp in acromegaly compared to controls (18, 19) . Considering the mechanism discussed in the previous paragraph, mucosal hyperproliferation caused by elevated serum GH/IGF-I levels may explain the increased prevalence of hyperplastic polyp in acromegaly. Our study design of using an untreated acromegalic population may have clarified this relationship in this study. Interestingly, two acromegalic patients in this study had multiple hyperplastic polyps at the proximal colon. In general, hyperplastic polyps are more frequently located at the distal colon, and most of them are innocuous. In contrast, multiple, large, and proximally located hyperplastic polyps may have the potential to develop into neoplasm. Since our study was limited in the number of subjects, we could not determine whether acromegalic patients tend to be more likely to have this "distinct" latter type of hyperplastic polyp compared to nonacromegalic patients. However, it would be worthwhile to further investigate hyperplastic polyps-neoplasm in patients with acromegaly. Among acromegalic patients, determining which patients are at higher risk of colorectal neoplasm remains uncertain. Based on the clinical characteristics of our study subjects, male gender, age ≥ 40 yr, current smoking, and higher serum GH levels might be potential predictors of colorectal neoplasm among acromegalic patients. Age has been suggested in previous literature as a predictor of colorectal cancer among acromegalic patients; more than 50 (11, 12) or 40 yr old (38) . In screening guidelines for acromegalic patients proposed by Jenkins and Fairclough (38) , it was also suggested that the patients with acromegaly should be screened by regular colonoscopy after age 40. However, in order to achieve efficient screenings, we may need to individualize screening intervals and methods by utilizing other clinical information such as smoking and serum GH levels. A better understanding about the predictors of colorectal neoplasm among acromegalic patients is needed.
Our study has some limitations related to study design and population. Since we assessed cross-sectional associations of the colonic lesions with acromegaly and serum levels of GH, our study cannot address any causal relationships between these variables. Further studies are needed to address the causality and mechanisms of colonic tumorigenesis in this population.
In this study, potential controls who had received polypectomy within 3 yr and those who had unbiopsied colonic lesions were both excluded, which may distort our risk estimates. We performed a sensitivity analysis including the controls who had been excluded by reason of "recent history of polypectomy" or "unbiopsied lesion" (n = 105). We assumed the highest possible prevalence of colonic lesions between these two groups based on the endoscopic findings in the rest of the study population (22%, 42%, and 28% for hyperplastic polyp, adenoma, and carcinoma, respectively). Including these potential controls under this scenario attenuated the odds of hyperplastic polyp, adenoma, and carcinoma in acromegalic patients by 25%, 29%, and 43%, respectively, from the original odds ratios. However, while odds were attenuated, results still suggested an increased risk of disease in acromegalic patients compared to controls.
In conclusion, this study showed that the acromegalic patients were at an increased risk of colorectal neoplasm as well as hyperplastic polyp. The study also suggests that GH (IGF-I axis) may be related to the increased prevalence of colorectal lesions. These findings may provide relevant information for a better understanding of the pathophysiology of colorectal neoplasm and for developing more efficient screening guidelines in acromegaly.
